Weaknesses in US laboratory system need addressing to improve disease response

Weaknesses in the United States laboratory system, which were illuminated during the COVID-19 pandemic, underscore a need for policy changes to improve the country’s infectious disease response, according to a new analysis by a Weill Cornell Medicine investigator.

The analysis, published in the March issue of Health Affairs, was co-authored by Dr Jay Varma, Professor of Population Health Sciences and Medicine at Weill Cornell Medicine, Dr Jill Taylor of the Association of Public Health Laboratories, and Dr Joshua Sharfstein, Vice Dean for Public Health Practice and Community Engagement at the Johns Hopkins Bloomberg School of Public Health. The authors suggest government and private institutions collaborate to implement systemic changes to improve the monitoring and tracking of highly transmissible diseases.

“The laboratory system in the US is a patchwork of different organisations inside and outside of the government that have to work together in a seamless way to ensure that the American people have the highest quality diagnostic testing and that public health organisations receive data in a clear and quick way to take immediate action,” said lead author Dr Varma, who is also a director of the Cornell Center for Pandemic Prevention and Response.

With inefficient test execution and faulty test design during the COVID-19 pandemic, the Centers for Disease Control and Prevention’s (CDC) ‘stepwise’ approach to developing tests was too slow and insufficient to match the pace of the highly transmissible virus – setting up the institution to be a ‘single point of failure’ when monitoring disease spread, writes the authors. These problems arose again during the 2022 outbreak of Mpox, with the nation facing medical supply shortages and delayed test results due to the lack of clarity and coordination between many different sources reporting public health data.

To address these limitations, the authors acknowledged the need for federal financial investment and provided estimated costs of improving staffing, equipment, infrastructure, and creating secure data systems for the US health system over the next ten years. The authors also suggested internal improvements in CDC structure and operations, and having the institution collaborate with public and private labs to create a ‘national road map’ defining roles and responsibilities for all involved at each stage of a disease outbreak as it evolves. Specifically, the CDC can work with the Food and Drug Administration (FDA) to create a regulatory pathway for at-home tests and with the National Institutes of Health (NIH) to coordinate a national database for standardised clinical information.

In establishing public-private partnerships, the US laboratory system can improve the reliability and efficacy of current disease tracking methods. Furthermore, the authors encourage expanding the Strategic National Stockpile and increasing access to testing resources, especially early in an outbreak – key investments to prepare the United States for the next pandemic.


  • Varma JK, Taylor J, Sharfstein JM. Planning For The Next Pandemic: Lab Systems Need Policy Shift To Speed Emerging Infectious Disease Warning And Tracking. Health Aff (Millwood). 2023;42(3):366-373. doi:10.1377/hlthaff.2022.01211

Latest Issues

Med-Tech Innovation Expo

NEC, Birmingham
5-6 June, 2024


DoubleTree by Hilton Brighton Metropole
10-12 June, 2024

Infection Diagnostics Symposium 2024

IET Austin Court, Birmingham
26-27 June, 2024

SHOT Symposium 2024

Mercure Manchester Piccadilly Hotel
9 July, 2024